Compare Smith & Nephew plc (SNN) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Xylem, Inc. — how do they compare? Smith & Nephew plc trades at $27.96 (market cap $11.62B), while Xylem, Inc. trades at $107.8 (market cap $25.13B). The key difference: Xylem, Inc. is far larger — about 2.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.86%). Which is the better fit depends on your goals.
| SNN | XYL | |
|---|---|---|
Market Cap | $11.62B | $25.13B |
Sector | Health | Industrials |
52-Week High | $38.53 | $152.95 |
52-Week Low | $27.80 | $105.69 |
Enterprise Value | $14.66B | $26.91B |
Dividend Yield | 2.86% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $27.87, down 3.46% today and near a 52-week low. Technical indicators are bearish, but oversold RSI levels suggest potential for a rebound. Fundamentally, the company shows strong revenue growth to $6.16 billion in 2025 and a net income margin of 10.08%, though recent guidance cuts and CFO departure have weighed on sentiment. A dividend of $0.31 is scheduled for payment in November 2026.
The outlook is cautious due to competitive pressures and execution risks, but valuation metrics like a P/E of 18.96 appear reasonable. Analyst consensus is Hold, with 65% recommending neutrality. Upside depends on improved operational performance and stabilization in key markets.
Xylem (XYL) trades at $108.81, up 2.95% in the last session, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.46 exceeding expectations. Revenue growth has been steady, rising from $5.5B in 2022 to $9.0B in 2025, while net income margins improved to 10.59%. Recent corporate actions include a dividend declaration and strategic acquisitions to bolster its industrial presence.
The outlook for XYL is positive based on earnings momentum and strategic initiatives, though technical indicators suggest near-term caution. Upside potential is supported by a consensus price target of $152.29, implying significant appreciation. Risks include execution of recent acquisitions and macroeconomic pressures on industrial demand. The stock presents a compelling opportunity for long-term investors focused on water infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
